Bristol Myers Squibb and Cellares announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380 million in upfront and milestone payments. As part of the agreement, Cellares will optimize, automate, and tech-transfer select Bristol Myers Squibb CAR T cell therapies onto its automated and high-throughput manufacturing platform, the Cell Shuttle?. Cellares will dedicate multiple Cell Shuttle and Cell Q? systems with fully automated, high-throughput quality control for Bristol Myers Squibb?s exclusive use.

The Cell Shuttles and Cell Qs will be deployed in Cellares? Smart Factories in the U.S., EU, and Japan. Manufacturing cell therapies is both operationally and technically complex.

Because cell therapies are rapidly transforming the way many different diseases are treated, the demand for these treatments is increasing significantly. This collaboration enables Bristol Myers Squibb to expand its manufacturing capacity, meeting the growing demand for its diverse range of cell therapies through a platform that is scalable and has the potential to improve turnaround time, bringing the promise of cell therapies to more patients faster. This agreement expands upon the existing collaborations between Bristol Myers Squibb and Cellares.